10-Q: Protalix Reports Q3 2025 Results, Advances Gout Program

Protalix BioTherapeutics reported a net income of $2.355 million for Q3 2025, driven by increased sales to Fiocruz and R&D services, while advancing its PRX-115 gout treatment to Phase 2 clinical trials.

Summary

• Net income for the three months ended September 30, 2025, was $2.355 million, compared to $3.236 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(1.100) million, an improvement from a net loss of $(3.562) million for the nine months ended September 30, 2024.
• Total revenue for the three months ended September 30, 2025, was $17.851 million, a slight decrease from $17.959 million in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, increased by 24% to $43.622 million, compared to $35.181 million in the same period of 2024.
• Research and Development expenses increased by 50% to $4.5 million for Q3 2025 and by 58% to $13.9 million for the nine months ended September 30, 2025, primarily due to preparations for the planned Phase 2 clinical trial of PRX-115.
• Cash and cash equivalents and short-term bank deposits totaled $29.4 million as of September 30, 2025.
• The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the requested 2 mg/kg body weight infused every four weeks (E4W) dosing regimen for Elfabrio, for which a re-examination has been requested.
• The Investigational New Drug (IND) application for PRX-115, a treatment for uncontrolled gout, has become effective, with the Phase 2 clinical trial expected to commence in the fourth quarter of 2025.
• The company believes its current liquidity is sufficient to satisfy capital needs for at least 12 months from the report issuance date.

Sentiment

Score: 5

Explanation: While there is progress in the pipeline (PRX-115 Phase 2) and year-over-year revenue growth, the quarter-over-quarter revenue decline, significant increase in cash used in operations, and the negative CHMP opinion for Elfabrio's dosing regimen introduce considerable uncertainty. The company's reliance on future capital raises and the shrinking Gaucher market also temper enthusiasm.

Positives

• Net income for the three months ended September 30, 2025, was $2.355 million, indicating profitability for the quarter.
• Total revenue for the nine months ended September 30, 2025, increased by 24% to $43.622 million compared to $35.181 million in the same period of 2024.
• The net loss for the nine months ended September 30, 2025, improved to $(1.100) million from $(3.562) million in the prior year period.
• Sales to Chiesi for Elfabrio increased by $4.5 million and sales to Pfizer for Elelyso increased by $4.0 million for the nine months ended September 30, 2025.
• Sales to Fiocruz (Brazil) increased by $4.1 million for the three months ended September 30, 2025.
• The IND application for PRX-115 (uncontrolled gout) Phase 2 clinical trial became effective, with trial initiation expected in Q4 2025, following positive Phase 1 data.
• Cash and cash equivalents and short-term bank deposits of $29.4 million as of September 30, 2025, are believed to be sufficient for at least 12 months.
• Selling, General and Administrative expenses decreased by $1.0 million, or 11%, for the nine months ended September 30, 2025, compared to the same period in 2024.
• Financial income, net, for Q3 2025 was $0.1 million, a positive shift from financial expenses, net, of $0.1 million in Q3 2024, primarily due to lower notes interest expenses.
• A tax benefit of approximately $0.1 million was recorded for the three months ended September 30, 2025, compared to tax expenses of $0.6 million for Q3 2024.
• Tax reform legislation (H.R.1) enacted on July 4, 2025, restores current deductibility for domestic research expenditures beginning in 2025.

Negatives

• Net income for the three months ended September 30, 2025, decreased to $2.355 million from $3.236 million in Q3 2024.
• Total revenue for the three months ended September 30, 2025, decreased slightly by 1% to $17.851 million compared to $17.959 million in Q3 2024.
• Sales to Chiesi for Elfabrio decreased by $3.6 million and sales to Pfizer decreased by $0.6 million for the three months ended September 30, 2025.
• The EMA's CHMP issued a negative opinion on the requested 2 mg/kg every four weeks dosing regimen for Elfabrio, requiring a re-examination request.
• Research and Development expenses increased significantly by 50% to $4.5 million for Q3 2025 and 58% to $13.9 million for the nine months ended September 30, 2025, primarily due to PRX-115 development.
• Net cash used in operating activities was $14.0 million for the nine months ended September 30, 2025, a significant negative shift from cash provided of $4.7 million in the same period of 2024.
• Fiocruz's purchases of BioManguinhos alfataliglicerase (Elelyso in Brazil) have been significantly below agreed-upon purchase milestones, giving the company the right to terminate the Brazil Agreement.
• The company expects to continue to incur significant, increasing R&D expenses as product candidates advance.
• The global market for Gaucher disease is forecasted to grow at a compound annual growth rate (CAGR) of approximately -1.82% from 2024-2030, indicating a shrinking market.

Risks

• Risks related to the commercialization of Elfabrio, including market acceptance, competition, reimbursement, and regulatory actions (e.g., boxed warning in FDA approval).
• Possible disruption of operations due to military actions conducted by Israel with Hamas, Hezbollah, and others, including impacts on regulatory authorities, suppliers, collaborative partners, licensees, clinical trial sites, distributors, and customers, and the risk of a greater regional conflict.
• Risks related to the regulatory approval and commercial success of other product and product candidates.
• Risks related to expectations with respect to the projected market of products and product candidates.
• Failure or delay in the commencement or completion of preclinical studies and clinical trials due to factors like slow patient recruitment, unforeseen safety issues, dosing issues, lack of effectiveness, inability to demonstrate non-inferiority, investigator non-compliance, or insufficient funding.
• Delays in approval or potential rejection of applications with regulatory authorities (FDA, EMA) for product candidates, including the re-examination of the negative CHMP opinion for Elfabrio's 2 mg/kg E4W dosing regimen.
• Risks associated with global conditions and developments such as new tariffs, trade restrictions, supply chain challenges, inflationary environment, tight labor market, and banking industry instability.
• Risks related to transactions in public or private equity or debt markets to raise capital.
• Risks relating to the evaluation and pursuit of strategic partnerships.
• The risk that clinical trial results will not support safety or efficacy claims, or that product candidates will have undesirable side effects.
• Risks relating to managing relationships with collaborators, distributors, or partners (Pfizer, Chiesi).
• Risks related to the amount and sufficiency of cash and cash equivalents and short-term bank deposits.
• Risks relating to changes to interim, top-line, or preliminary data from clinical trials.
• Risks relating to Fiocruz's compliance with purchase obligations under the Brazil Agreement, which may have a material adverse effect and could result in termination.
• Risk of significant lawsuits, including stockholder litigation.
• Dependence on third-party providers of services and supplies, including clinical trial services.
• Inherent risks and uncertainties in developing drug platforms and products.
• The impact of development of competing therapies and/or technologies by other companies.
• Risks related to the supply of drug products to Pfizer.
• Potential product liability risks and risks of securing adequate levels of related insurance coverage.
• The possibility of infringing a third-party's patents or other intellectual property rights and the uncertainty of obtaining patents covering products and processes and successfully enforcing intellectual property rights against third-parties.
• Risks relating to changes in healthcare laws, rules, and regulations in the United States or elsewhere.
• Variability in Chiesi's and Pfizer's/Fiocruz's ordering patterns for Elfabrio and Elelyso, which may not directly reflect patient demand and can result in period-to-period revenue fluctuations.

Future Outlook

The company expects to continue incurring significant and increasing research and development expenses as its product candidates advance through preclinical and clinical trials. While revenues from Elfabrio and Elelyso sales are anticipated to increase, they may not be sufficient to fund all future expenditures, potentially necessitating additional financing, which could be challenging given stock price volatility. The Phase 2 clinical trial for PRX-115 is expected to commence in the fourth quarter of 2025. The company is evaluating new accounting standards (ASU 2024-03 and ASU 2023-09) which may expand disclosures, but does not expect a material impact from ASU 2025-05.

Management Comments

• "We expect to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates."
• "We believe that its cash and cash equivalents and short-term bank deposits as of September 30, 2025, are sufficient to satisfy the Companys capital needs for at least 12 months from the date that these financial statements are issued."
• "We expect to initiate the [PRX-115 Phase 2] trial in the fourth quarter of 2025."
• "We do not anticipate that these Chiesi ordering patterns will change until the demand characteristics for Elfabrio stabilize, the launch of Elfabrio matures and Elfabrios share of the market for Fabry disease treatment grows."
• "We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled gout, regardless of treatment history."

Industry Context

The global market for Gaucher disease, where Elelyso competes, is projected to remain flat at approximately $1.7 billion in 2025 and then decline at a CAGR of -1.82% from 2024-2030. In contrast, the global market for Fabry disease, where Elfabrio competes, is forecasted to grow to approximately $2.2 billion in 2025 and expand at a CAGR of 8.19% from 2024-2030, reaching $3.4 billion in annual sales by 2030. The company's focus on rare and orphan diseases, leveraging its unique plant cell-based ProCellEx platform, positions it in specialized, high-need markets. The advancement of PRX-115 for uncontrolled gout addresses a significant unmet need, as existing therapies like Krystexxa carry black box warnings and have limited market presence in some regions.

Comparison to Industry Standards

• In Gaucher disease, Elelyso is an alternative enzyme replacement therapy (ERT) to Sanofi's Cerezyme and Takeda's Vpriv, operating in a market forecasted to decline at a CAGR of -1.82% from 2024-2030.
• In Fabry disease, Elfabrio competes with established ERTs such as agalsidase beta (Sanofi's Fabrazyme), agalsidase alfa (Takeda's Replagal), and Amicus Therapeutics' Galafold, within a market projected to grow at an 8.19% CAGR from 2024-2030.
• For uncontrolled gout, PRX-115 is being developed as a potential alternative to existing recombinant uricases like Krystexxa (pegloticase) and Elitek. Krystexxa has a black box warning for anaphylaxis and is no longer marketed in the European Union for commercial reasons, suggesting a significant unmet need for safer and more effective therapies, which PRX-115 aims to address with its long half-life and reduced immunogenic risk demonstrated in preclinical data.
• Protalix is noted as the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension (ProCellEx system), highlighting a unique technological advantage in biopharmaceutical manufacturing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any material legal proceedings.

Stakeholder Impact

• Shareholders: Potential for future dilution from equity offerings, stock price volatility, and continued R&D expenses leading to losses. The negative CHMP opinion for Elfabrio could impact future revenue potential.
• Employees: Management change (new CFO) and grants of stock options and restricted stock provide incentives.
• Customers (Pfizer, Chiesi, Fiocruz): Variability in ordering patterns from partners can affect Protalix's revenue recognition. Fiocruz's failure to meet purchase milestones could lead to termination of the Brazil Agreement.
• Patients (Fabry, Gaucher, Gout): Elfabrio's approval in multiple regions provides treatment options. PRX-115 advancing to Phase 2 offers hope for uncontrolled gout patients. The negative CHMP opinion for Elfabrio's 2 mg/kg E4W dosing regimen could limit treatment flexibility in the EU.
• Creditors: Repayment of 2024 Notes in full reduces debt obligations.

Next Steps

• Initiate the Phase 2 clinical trial of PRX-115 for uncontrolled gout in the fourth quarter of 2025.
• Continue research and development efforts for current and future product candidates.
• Monitor and potentially pursue strategic marketing partnerships and collaboration programs.
• Chiesi is sponsoring a pediatric clinical trial (FLY Study) for Elfabrio, with recruitment commenced.
• Chiesi is recruiting patients for the Japanese RISE study for Elfabrio.
• Protalix and Chiesi have requested a re-examination of the negative CHMP opinion for Elfabrio's 2 mg/kg E4W dosing regimen.
• Address future funding requirements through various financing options, including potential equity offerings.
• Evaluate new accounting standards (ASU 2024-03 and ASU 2023-09) for potential expanded disclosures.

Key Dates

Recommendation

While the company shows promising pipeline development with PRX-115 advancing to Phase 2 and year-over-year revenue growth, the quarter-over-quarter revenue decline, significant increase in cash used in operations, and the negative CHMP opinion for Elfabrio's dosing regimen introduce considerable uncertainty. The Fabry market is growing, but the Gaucher market is shrinking. The company's reliance on future capital raises and the potential for further dilution, coupled with geopolitical risks in Israel, suggest a 'Hold' recommendation. Investors should monitor the outcome of the Elfabrio re-examination, PRX-115 clinical trial progress, and the company's cash management closely before making further investment decisions.

Keywords

Protalix BioTherapeutics, PLX, Fabry disease, Gaucher disease, Elfabrio, Elelyso, pegunigalsidase alfa, taliglucerase alfa, PRX-102, PRX-115, PRX-119, gout, NETs-related diseases, enzyme replacement therapy, ERT, biopharmaceutical, plant cell-expressed protein, ProCellEx, SEC filing, 10-Q, financial results, clinical trials, R&D, corporate governance, risk factors, Chiesi, Pfizer, Fiocruz